LL-37 Peptide: What the Evidence Shows and Doesn't

LL-37 is a real human peptide with a well-studied role in immune defense. It is not an FDA-approved treatment for hormonal balance, weight loss, metabolic health, anti-aging or general vitality. Most of what exists in humans is early-stage research in narrow settings such as wounds and cancer trials, and the FDA has flagged compounded versions as a safety concern. This guide explains what LL-37 is, what the studies found, how "research grade" differs from approved or compounded products, and what to ask a clinician if you are considering it.

TL;DR

LL-37 is the only human cathelicidin: a 37-amino-acid immune peptide your body makes locally from a precursor called hCAP18.
Lab studies show antimicrobial and immune-signaling effects, but they can be protective or harmful depending on tissue and concentration. "Immune booster" is an oversimplification.
The best-known human trial, in venous leg ulcers, did not show a significant benefit in the full study group. A positive result in large ulcers came from a post-hoc subgroup.
FDA lists compounded cathelicidin LL-37 among bulk substances that may present significant safety risks. A registered facility or a certificate of analysis is not FDA approval.
LL-37 is not a substitute for testosterone, estrogen or progesterone therapy, or GLP-1 treatment. Start with your actual goal and a qualified clinician.

What LL-37 is
What LL-37 does in the body
LL-37 benefits: what human studies actually exist
Safety: what FDA says about compounded LL-37
Approved, compounded, research-grade: three different things
Our perspective
Questions to bring to a clinician
Where hormone and weight questions start instead
Spotting weak claims about LL-37
FAQ
Sources

What LL-37 is

LL-37 is a host-defense peptide, part of the innate immune system's first line of response. According to NIH's PubChem entry, it has the molecular formula C205H340N60O53 and a molecular weight of about 4,493 g/mol. The name comes from the two leucines at its start and its length of 37 amino acids. Other names include cathelicidin LL-37 and, in some drug-development contexts, ropocamptide.

Your body makes it when the larger precursor hCAP18, encoded by the CAMP gene, is cleaved. A 2025 review of LL-37 and local infection describes it as a host-defense peptide produced where it is needed, such as skin, mucosal surfaces and immune cells. It is made locally, turns over quickly and circulates at low levels. That matters for the next point: an injectable product is not the same thing as the peptide your cells make in context, and it is not a lab value you can "top up."

What LL-37 does in the body

The research literature describes several functions. Per the 2025 review, these include:

disrupting the membranes of some bacteria, viruses and fungi
binding endotoxin
affecting biofilms
recruiting immune cells
shaping inflammatory signaling

A review of LL-37 in immunomodulation and a review of its antimicrobial and anti-biofilm potential cover this ground in more depth.

Two caveats shape how to read all of it.

Biology is not treatment. These are mechanisms seen in cells, animals and tissue. They do not show that a self-administered dose treats an infection or improves wellness.

The effects cut both ways. The 2025 review notes LL-37 has both anti-inflammatory and pro-inflammatory effects and is cytotoxic to many human cell types at experimental concentrations (1 to 10 µM in the studies it cites). The same peptide can help clear a local infection in one environment and amplify inflammation or tissue injury in another. That is why a blanket "immune boost" is not a clinically reliable rationale. We cover the broader problem in Peptides for Immunity: Why "Boosting" Misses the Evidence.

LL-37 benefits: what human studies actually exist

People searching for LL-37 benefits usually find supplier pages and clinic blogs listing recovery, immunity and anti-inflammatory effects. The human evidence behind those lists is thin. Here are the two best-documented human studies.

Venous leg ulcers: a mixed result

The HEAL LL-37 trial was a phase IIb, double-blind, placebo-controlled study of 148 people with hard-to-heal venous leg ulcers. Participants received topical LL-37 at 0.5 or 1.6 mg/mL, or placebo, alongside compression therapy. Their mean age was 67.6 years, and the median ulcer had lasted 20.3 months.

The full-population analysis found no significant improvement over placebo. A post-hoc subgroup with ulcers of at least 10 cm² showed statistically significant signals. That is a hypothesis for a future trial, not proof. It also says nothing about injections, body composition, hormones or healthy adults.

Trial arms and qualified LL-37 findings

Melanoma: a research protocol, not a regimen

A completed M.D. Anderson study tested LL-37 injected directly into selected melanoma tumors, weekly for up to 8 weeks, in up to 36 participants. The registry identifies the agent as investigational, not FDA approved and not commercially available. Dose-finding and institutional oversight defined that study. It cannot be turned into a subcutaneous schedule for "optimization."

What is missing

We found no adequate human trials showing that LL-37 improves testosterone levels, menopausal symptoms, weight, energy or longevity. Absence of evidence is not proof of harm, but it means any claim of those benefits is unsupported. A review of LL-37's structures and activity frames it as an innate-immunity molecule, not a hormone-replacement drug.

Safety: what FDA says about compounded LL-37

FDA keeps a list of bulk drug substances nominated for compounding that may present significant safety risks (category 2). Cathelicidin LL-37 appears there. FDA says compounded drugs containing it may pose a risk of immunogenicity for certain routes of administration, with complexities around peptide-related impurities and characterization of the active ingredient. It also says it lacks enough safety information to know whether the peptide could harm humans. The same entry points to nonclinical findings that raised concerns about male reproduction and possible tumor-promoting effects in some tissues.

In plain terms:

Immunogenicity means the immune system could react to the product itself.
Impurities and aggregation can occur with injectable peptides, and they are hard to detect without proper testing.
Limited human data means nobody can give you a reliable list of side effects or a safe dose for a wellness purpose.

That last point is why we do not give doses, schedules, reconstitution amounts or injection steps for LL-37. Nobody can responsibly supply them for an investigational peptide outside a protocol.

Approved, compounded, research-grade: three different things

Labels in this space blur categories. This table separates them.

Category	What it means	Applies to LL-37?
FDA-approved drug	FDA reviewed evidence of safety and effectiveness for a specific use	No approved LL-37 product for hormonal, weight or wellness use
Compounded drug	Made by a licensed pharmacy for an individual patient under rules such as section 503A	FDA has flagged compounded LL-37 as a potential significant safety risk
Research-grade or "for research use only"	Sold for lab work, not for human use	Common online; not intended for people
Investigational	Used within a registered trial under oversight	Yes, for example the melanoma and ulcer studies

FDA explains that 503A compounding generally requires the bulk substance to meet a USP/NF monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulks list, with certificate-of-analysis and supplier-registration requirements on top. Those rules do not make any individual compounded product FDA-approved. A registered facility, a certificate of analysis or a "purity 98%" label is not approval, proof of efficacy or evidence that an injectable suits you.

Our related guides go deeper on this: how US patients can obtain peptides legally, the risks of research peptides and overseas peptide suppliers.

Our perspective

We publish educational information about hormone care, weight management and clinician consultations. People often arrive having read that a peptide such as LL-37 can "reset" immunity or support vitality. What the sources show is more modest, and we think readers deserve that clearly.

If your real goal is relief from menopausal symptoms, low testosterone, weight management or fatigue, those have condition-specific evaluation and, in several cases, approved or guideline-supported options. LL-37 is not one of them. The better first step is to name the goal, get appropriate labs, and discuss options with a licensed clinician who can weigh your history.

We do not infer product approval, sourcing, purity, testing or clinical results from marketing copy, ours or anyone else's. Whether a clinician prescribes anything at all is that clinician's decision, and we cannot promise a prescription.

— AirMedFit

Questions to bring to a clinician

If you are still considering LL-37, a consultation is the right place to test the idea. Useful questions:

What is the goal? Name the symptom or condition: recurrent infections, a slow-healing wound, menopause symptoms, low testosterone, obesity, insulin resistance.
What is the evidence for this specific use? Ask for the study, the population and whether the result was prespecified or post hoc.
Is there an approved or guideline-supported option first? For most goals there is.
Is the product FDA-approved, compounded or research-grade? Ask who makes it and how the pharmacy meets FDA's compounding requirements.
What are the known risks for me? Mention autoimmune conditions, cancer history, pregnancy plans and current medicines.
How would we monitor and when would we stop? A plan with endpoints beats open-ended use.

For a wound that is not healing, infection symptoms, or sudden worsening of any condition, see a physician in person rather than researching peptides. Chronic leg ulcers in particular need assessment of circulation and standard compression care.

Where hormone and weight questions start instead

If your search for LL-37 began with hormone, weight or energy concerns, evidence-based evaluation usually begins with symptoms, history and labs. Our site lists a Doctor's Consultation page and consultation options. As published when we last checked, an Async Doctor's Consult is listed at 49 USD one-off and a Sync Doctor's Consult at 120 USD one-off. Confirm current availability, scope, costs and follow-up on the page before you order.

AirMedFit also lists lab panels with home kits: Men's Essential at 129 USD one-off and Women's Essential at 139 USD one-off, as published. Labs can help frame a conversation about testosterone, menopause or metabolic health. They do not diagnose anything by themselves, and any treatment decision stays with the clinician. Memberships for HRT and TRT are listed on the TRT and HRT collection, without a published price, so check the page for current terms.

Where hormone and weight questions start instead — overview diagram

Spotting weak claims about LL-37

When you read a product page or social post, check for these patterns:

Cell-study claims presented as human results. "Kills bacteria" in a dish is not "treats your infection."
Citing the ulcer trial without the caveat. The overall result was not significant. The subgroup finding was post hoc.
"Physician-supervised" with no details. Supervision should mean a named clinician who evaluates you, reviews your labs and follows up. Ask what that involves.
Purity numbers as proof of safety. Purity on a certificate does not address immunogenicity or whether the product suits you.
No mention of FDA status. Honest sellers say whether a product is approved, compounded or for research only.
Dosing guides for injectables. An investigational peptide has no established wellness dose.

FAQ

What does peptide LL-37 do?

In the body, LL-37 helps defend against microbes and signals to immune cells, and it can raise or lower inflammation depending on context. Those functions are documented in laboratory and biological research. They do not show that a supplied injection improves health in healthy adults.

What are the side effects of LL-37 treatment?

There is no established side-effect profile for wellness use because there are no adequate human trials for it. FDA has flagged possible immunogenicity and impurity concerns for compounded LL-37, and says it lacks enough safety information. Laboratory work also shows cytotoxicity to human cells at higher concentrations. Talk to a physician before considering any LL-37 product.

Where can I get LL-37 peptide?

No FDA-approved LL-37 drug exists for consumer use. Online sellers market "research use only" material that is not intended for humans, and compounded versions are flagged by FDA. The only legitimate human access we found is through registered clinical trials, which you can look up on ClinicalTrials.gov. A clinician can discuss whether any option is appropriate for you.

When to take LL-37 peptide?

There is no evidence-based timing or dose for LL-37 in wellness use, so we do not give one. Research uses were protocol-specific: topical gel applied to ulcers in one trial, and injections into tumors in another. Anyone offering a general schedule is going beyond the evidence.